| P2093 | author name string | Gunter P Eckert | |
| | Walter E Mueller | |
| | Christopher Kirsch | |
| P2860 | cites work | Polarization of the fluorescence of macromolecules. I. Theory and experimental method | Q24531310 |
| | Lipid rafts and signal transduction | Q28131735 |
| | Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study | Q28366850 |
| | A new role for apolipoprotein E: modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes. | Q30329988 |
| | The role of cholesterol in the biosynthesis of beta-amyloid | Q30779994 |
| | Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-pick type C cells | Q31583322 |
| | Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance | Q31796937 |
| | Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease | Q33609376 |
| | Amyloid and lipids in the pathology of Alzheimer disease. | Q33706311 |
| | Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. | Q33921362 |
| | Non-lipid-related effects of statins | Q33924588 |
| | Cholesterol depletion induces large scale domain segregation in living cell membranes | Q33949091 |
| | Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts | Q34088442 |
| | A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease | Q34094305 |
| | Cholesterol attenuates the membrane perturbing properties of beta-amyloid peptides | Q44199468 |
| | Lipid rafts of purified mouse brain synaptosomes prepared with or without detergent reveal different lipid and protein domains | Q44288428 |
| | Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). | Q48164740 |
| | In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors | Q48181561 |
| | Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change. | Q48202659 |
| | beta-Amyloid protein amplifies calcium signalling in central neurons from the adult mouse | Q48232512 |
| | Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol | Q48482911 |
| | Transbilayer distribution of cholesterol is modified in brain synaptic plasma membranes of knockout mice deficient in the low-density lipoprotein receptor, apolipoprotein E, or both proteins. | Q48610121 |
| | Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease | Q48761995 |
| | Plasma membrane lipid composition modulates action of anesthetics. | Q51803260 |
| | Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? | Q52531799 |
| | Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease. | Q52539745 |
| | Transbilayer effects of ethanol on fluidity of brain membrane leaflets. | Q52547157 |
| | Temperature, pressure and cholesterol effects on bilayer fluidity; a comparison of pyrene excimer/monomer ratios with the steady-state fluorescence polarization of diphenylhexatriene in liposomes and microsomes | Q57251360 |
| | Transmembrane distribution of sterol in the human erythrocyte | Q67919225 |
| | Low-density lipoprotein receptor on endothelium of brain capillaries | Q69653609 |
| | Determination of lipid phosphorus in the nanomolar range | Q71601310 |
| | Cholesterol domains in biological membranes | Q72279452 |
| | Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages | Q72325369 |
| | Modulation of ATPase activities of human erythrocyte membranes by free fatty acids or phospholipase A2 | Q72534985 |
| | Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet | Q78181101 |
| | How cells handle cholesterol. | Q34094514 |
| | Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis | Q34117380 |
| | Cholesterol metabolism in the brain | Q34193085 |
| | Use of statins in CNS disorders | Q34300585 |
| | Essential fatty acids as possible mediators of the actions of statins | Q34327189 |
| | Membrane-disordering effects of beta-amyloid peptides | Q34332530 |
| | Recent advances in membrane microdomains: rafts, caveolae, and intracellular cholesterol trafficking | Q34420952 |
| | Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors | Q34432988 |
| | Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors | Q34460973 |
| | Statins in the 21st century: end of the simple story? | Q34481748 |
| | A comparison of clinical outcome studies among cholesterol-lowering agents | Q34495746 |
| | Statins and the risk of dementia | Q34511970 |
| | Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo | Q34514599 |
| | Cholesterol, A beta and Alzheimer's disease | Q34553838 |
| | Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons | Q34663462 |
| | Apolipoprotein-E allele-specific regulation of nitric oxide production. | Q34699682 |
| | Location of diphenylhexatriene (DPH) and its derivatives within membranes: comparison of different fluorescence quenching analyses of membrane depth | Q34747493 |
| | Cholesterol and Alzheimer's disease | Q34797411 |
| | Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. | Q35897595 |
| | A fluid connection: cholesterol and Abeta | Q35906228 |
| | Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase | Q36225423 |
| | Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis | Q36650009 |
| | Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. | Q37176000 |
| | Alzheimer's disease: a central role for amyloid | Q40701623 |
| | Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide | Q40777105 |
| | Use of fluorescent probes to monitor molecular order and motions within liposome bilayers | Q40781479 |
| | Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid | Q40807391 |
| | Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors | Q40922775 |
| | Recent advances in membrane cholesterol domain dynamics and intracellular cholesterol trafficking | Q41226568 |
| | Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein | Q41226800 |
| | Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors | Q41445253 |
| | Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture | Q41639392 |
| | Charged anaesthetics alter LM-fibroblast plasma-membrane enzymes by selective fluidization of inner or outer membrane leaflets | Q42854763 |
| | Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice | Q43575926 |
| | Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. | Q43578320 |
| | Alzheimer's disease. Bad for the heart, bad for the mind? | Q43614473 |
| | Effects of aging and beta-amyloid on the properties of brain synaptic and mitochondrial membranes | Q43804305 |
| | Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain | Q43885523 |
| | Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains | Q43889089 |
| | Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. | Q43906981 |
| | Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice | Q43945469 |
| | Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice | Q43945499 |
| | Potential neurological value of statins increases | Q44013439 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 843-856 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Statin effects on cholesterol micro-domains in brain plasma membranes | |
| P478 | volume | 65 | |